PIPA: a phase Ib study of beta-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) and fulvestrant (FUL) in PIK3CA-mutant (mt) ER-positive and taselisib (T) plus palbociclib (P) in PIK3CA-mutant (mt) ER-negative advanced breast cancer
Pascual, J MacPherson, IR Armstrong, Anne C Ward, SE Parmar, M Turner, AJ Bye, H Proszek, P Dodson, A Garcia-Murillas, I
Pascual, J
MacPherson, IR
Armstrong, Anne C
Ward, SE
Parmar, M
Turner, AJ
Bye, H
Proszek, P
Dodson, A
Garcia-Murillas, I
Citations
Altmetric:
Abstract
Description
Date
2019
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Pascual J, MacPherson IR, Armstrong AC, Ward SE, Parmar M, Turner AJ, et al. PIPA: a phase Ib study of ?-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) and fulvestrant (FUL) in PIK3CA-mutant (mt) ER-positive and taselisib (T) plus palbociclib (P) in PIK3CA-mutant (mt) ER-negative advanced breast cancer. J Clin Oncol. 2019;37(15_suppl):1051-.